ClinicalTrials.gg
CompletedNCT01317628Updated Oct 29, 2013

Effects of Tobacco Smoke Exposure on Epigenetic Signatures and Immunotoxicological Reactions

An interventional study of Tobacco smoke reduction trial intervention program in The Study Focused on Reducing Tobacco Smoke Exposure for Child., sponsored by National Taiwan University Hospital. Completed. Open to participants aged 12 Years to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-10-29.

Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
12 Years to 16 Years
Sex
All
01

Study summary

Researchers have noted that active smoke exposure was possibly related to epigenetic mechanism,and may further influence reactive immunotoxicological reaction on human beings. Some studies have been reported that smoking reduction would decrease the prevalence of respiratory symptoms and urinary cotinine level, but the underlying epigenetic mechanism and the functional changes of immunotoxicological system were still unclear. We plan to examine the causal relationship between smoking reduction and alterations in epigenetic signatures/immunotoxicological reactions. Teenager Smoking Reduction Trial (TSRT) will be population-based trial among teenagers. Eligible teenagers will be recruited in Taipei City and urinary cotinine level will be used to monitor the exposure status of active smoking at baseline, 1-month and 3-month of the intervention process. We will assess the potential change in immunotoxicological markers, including Th1/Th2 cytokines and clinical immunological measurements, before and after the intervention program. Furthermore, whole-genome methylation and miRNA expression microarrays will be used to search candidate genes for teenager smoking exposure. We plan to develop a prediction model for immunotoxicological reaction by utilizing epigenetic signature data from microRNA expression and DNA methylation profiles based on machine learning methodologies. We will also establish a personalized epigenetic prediction model for allergy development and build the risk assessment platform for immunotoxicological reaction under tobacco smoke exposure. Finally, we will examine the causal relationship between epigenetic signatures and immunotoxicological reactions under an independent children's cohort.

Read the detailed description

Teenager Smoking Reduction Trial (TSRT)

  1. Study subjects

    TSRT is a solution-oriented trial aiming to evaluate the effectiveness of tobacco smoke reduction among teenagers. Eligible teenagers will fit the following criteria: (a) age between 12 and 16 years old; (b) have active smoke habits in past 6 months; (c) amount of smoke exceed 10 cigarettes per week. The subjects will be recruited from our previous database for schoolchildren. Telephone interview will be used to screen the eligibility for the teenagers. Recruitment will occur over 3-month period from 2011 April to June. The procedure for TSRT is showed in figure 2. In this plan, we will recruit at least 31 asthmatic children and 31 non-asthmatic children who have active smoke habits.

  2. Data collection

A baseline data and at the 1-month and 2-month follow-up visits, the primary caregiver provided data by personal interview on parents reports. The demographic information in questionnaires included age, gender, level of education.

Teenagers will report the frequency of cigarette smoking by using a structured questionnaire. The definition of tobacco smoke exposure including: (a) ''Do you currently smoke?''-yes/no; (b) ''When did you begin to smoke regularly?''; (c) Smokers were also asked for the number of cigarettes they smoked on an average day. Nicotine dependence will be examined by using structure questionnaires from Fagerstrom model.

We will contact eligible teenagers individually to get informed consent before data collection. The effects of our teenager smoking reduction intervention program will be assessed by primary outcomes such as cotinine/creatinine ratio (CCR) and the status of tobacco smoke exposure from questionnaire. No matter which group the participant belongs to, intervention and usual control group, the secondary outcomes in all participants will be tested as follows:

  1. Cytokines. We will test levels of interleukin 4, 5, 13 (IL-4, 5, 13), tumor necrosis factor-α (TNF-α), interferon-gamma (INF-γ) and toll-like receptors 2, 4, 9 (TLR-2, 4, 9).
  2. Immunotoxicological reaction. We will determine levels of exhaled nitric oxide (eNO), serum eosinophil cationic protein (ECP) and absolute eosinophil count (AEC).
  3. Oxidative stress markers. Levels of the markers 8-hydroxy-2-deoxyguanosine (8-OHdG), malondialdehyde (MDA) and F2-isoprostane (Iso-P) will be examined.

After first session is applied, all participants will be tested for primary outcomes and secondary outcomes at baseline, month 1 and month 3 of the intervention process. We can then compare the biomarkers before and after the intervention program.

02

Conditions studied

  • The Study Focused on Reducing Tobacco Smoke Exposure for Child.

Keywords

  • tobacco smoke, intervention program
03

In context

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,609 studies on the registry; 574 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

(1) age between 12 and 16 years old; (2) Child had active smoking habit; and (3) have prior history of smoking habit.

Exclusion criteria

Exclusion Criteria:

We will exclude children who do not fit in with the inclusion criteria.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Other
    Lifestyle counseling

    Both the parents and children will receive 8 times intervention program weekly in first session. The telephone counseling will reduce the child's tobacco smoke exposure every weekly in second session. The interventionist and child jointly select behavioral goals for reducing tobacco smoke exposure for the child to work toward. The goals will be formalized as a written smoke exposure reduction plan for any of four specific behaviors, as relevant to that family: (a) smoking cessation for the child, (b) making the child's primary home smoke-free, (c) making non-home locations smoke-free.

    Behavioral: Tobacco smoke reduction trial intervention program

Interventions

  • BehavioralTobacco smoke reduction trial intervention program

    Both the parents and children will receive 8 times intervention program weekly in first session. The telephone counseling will reduce the child's tobacco smoke exposure every weekly in second session. The interventionist and child jointly select behavioral goals for reducing tobacco smoke exposure for the child to work toward. The goals will be formalized as a written smoke exposure reduction plan for any of four specific behaviors, as relevant to that family: (a) smoking cessation for the child, (b) making the child's primary home smoke-free, (c) making non-home locations smoke-free.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in cotinine level at 3 months

    Cotinine was the major proximate metabolite of nicotine,has been widely used as a biomarker of tobacco exposure. We will detect the urinary cotinine for children who had active smoking habit.

    Time frame: 3 month

  2. Change from Baseline in smoking status at 3 months

    The smoking status for children will be measure by structure questionnaire.

    Time frame: 3 months

Secondary outcomes

  1. Change from Baseline in DNA methylation at 3 months

    Time frame: 3 months

  2. Change from Baseline in immunological cytokine at 3 months

    Time frame: 3 months

  3. Change from Baseline in miRNA expression at 3 months

    Time frame: 3 months

  4. Change from Baseline in immunological function at 3 months

    Time frame: 3 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2011
First posted
Mar 17, 2011
Start
Apr 2011
Primary completionActual
Jun 2011
CompletionActual
Jun 2011
Last update
Oct 29, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01317628
Responsible party
Sponsor
First posted
Mar 17, 2011
Start date
Apr 2011
Primary completion
Jun 2011
Completion
Jun 2011
Last update
Oct 29, 2013

Study contacts

Yungling Lee, Ph.D
principal investigator · National Taiwan University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion